Cargando…
A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection
BACKGROUND & AIMS: Polymorphisms in the interleukin-28B (IL28B) gene are associated with outcomes from infection with hepatitis C virus (HCV). However, the role of these polymorphisms in protecting injection drug users who are at high risk for HCV infection but do not have detectable antibodies...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
W.B. Saunders
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194089/ https://www.ncbi.nlm.nih.gov/pubmed/21600205 http://dx.doi.org/10.1053/j.gastro.2011.04.005 |
_version_ | 1782213905833000960 |
---|---|
author | Knapp, Susanne Warshow, Usama Ho, K.M. Alexander Hegazy, Doha Little, Ann–Margaret Fowell, Andrew Alexander, Graeme Thursz, Mark Cramp, Matthew Khakoo, Salim I. |
author_facet | Knapp, Susanne Warshow, Usama Ho, K.M. Alexander Hegazy, Doha Little, Ann–Margaret Fowell, Andrew Alexander, Graeme Thursz, Mark Cramp, Matthew Khakoo, Salim I. |
author_sort | Knapp, Susanne |
collection | PubMed |
description | BACKGROUND & AIMS: Polymorphisms in the interleukin-28B (IL28B) gene are associated with outcomes from infection with hepatitis C virus (HCV). However, the role of these polymorphisms in protecting injection drug users who are at high risk for HCV infection but do not have detectable antibodies against HCV or HCV RNA (exposed uninfected) has not been demonstrated. We investigated whether these individuals have the IL28B genotype rs12979860-CC, which protects some individuals against HCV infection. METHODS: Seventy-four exposed uninfected individuals, 89 spontaneous resolvers, and 234 chronically infected individuals were genotyped to determine single nucleotide polymorphisms at IL28B.rs12979860. RESULTS: Exposed, uninfected individuals had a significantly lower frequency of the protective genotype (rs12979860-CC) than anti-HCV-positive spontaneous resolvers (41.9% vs 69.7%, respectively; P = .0005; odds ratio [OR], 0.31; 95% confidence interval [CI]: 0.16–0.60) but a similar frequency to patients who were chronically infected (41.9% vs 43.6%, respectively; P = ns). However, exposed, uninfected individuals had a significantly higher frequency of homozygosity for killer cell immunoglobulin-like receptor 2DL3:group 1 HLA-C (KIR2DL3:HLA-C1) than those with chronic infection (31.1% vs 13.3%, respectively; P = .0008; OR, 2.95; 95% CI: 1.59–5.49). For patients who spontaneously resolved infection, IL28B and KIR:HLA protected, independently, against chronic HCV infection, based on logistic regression and synergy analyses (synergy factor, 1.3; 95% CI: 0.37–4.75; P synergy = .6). CONCLUSIONS: IL28B and KIR2DL3:HLA-C1 are independently associated with spontaneous resolution of viremia following HCV exposure. Resistance to HCV infection in exposed uninfected cases is associated with homozygosity for KIR2DL3:HLA-C1 but not the single nucleotide polymorphism IL28B.rs12979860. Uninfected individuals are therefore a distinct population from patients who spontaneously resolve HCV infection. Distinct, nonsynergistic innate immune mechanisms can determine outcomes of HCV exposure. |
format | Online Article Text |
id | pubmed-3194089 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | W.B. Saunders |
record_format | MEDLINE/PubMed |
spelling | pubmed-31940892011-10-31 A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection Knapp, Susanne Warshow, Usama Ho, K.M. Alexander Hegazy, Doha Little, Ann–Margaret Fowell, Andrew Alexander, Graeme Thursz, Mark Cramp, Matthew Khakoo, Salim I. Gastroenterology Original Research BACKGROUND & AIMS: Polymorphisms in the interleukin-28B (IL28B) gene are associated with outcomes from infection with hepatitis C virus (HCV). However, the role of these polymorphisms in protecting injection drug users who are at high risk for HCV infection but do not have detectable antibodies against HCV or HCV RNA (exposed uninfected) has not been demonstrated. We investigated whether these individuals have the IL28B genotype rs12979860-CC, which protects some individuals against HCV infection. METHODS: Seventy-four exposed uninfected individuals, 89 spontaneous resolvers, and 234 chronically infected individuals were genotyped to determine single nucleotide polymorphisms at IL28B.rs12979860. RESULTS: Exposed, uninfected individuals had a significantly lower frequency of the protective genotype (rs12979860-CC) than anti-HCV-positive spontaneous resolvers (41.9% vs 69.7%, respectively; P = .0005; odds ratio [OR], 0.31; 95% confidence interval [CI]: 0.16–0.60) but a similar frequency to patients who were chronically infected (41.9% vs 43.6%, respectively; P = ns). However, exposed, uninfected individuals had a significantly higher frequency of homozygosity for killer cell immunoglobulin-like receptor 2DL3:group 1 HLA-C (KIR2DL3:HLA-C1) than those with chronic infection (31.1% vs 13.3%, respectively; P = .0008; OR, 2.95; 95% CI: 1.59–5.49). For patients who spontaneously resolved infection, IL28B and KIR:HLA protected, independently, against chronic HCV infection, based on logistic regression and synergy analyses (synergy factor, 1.3; 95% CI: 0.37–4.75; P synergy = .6). CONCLUSIONS: IL28B and KIR2DL3:HLA-C1 are independently associated with spontaneous resolution of viremia following HCV exposure. Resistance to HCV infection in exposed uninfected cases is associated with homozygosity for KIR2DL3:HLA-C1 but not the single nucleotide polymorphism IL28B.rs12979860. Uninfected individuals are therefore a distinct population from patients who spontaneously resolve HCV infection. Distinct, nonsynergistic innate immune mechanisms can determine outcomes of HCV exposure. W.B. Saunders 2011-07 /pmc/articles/PMC3194089/ /pubmed/21600205 http://dx.doi.org/10.1053/j.gastro.2011.04.005 Text en © 2011 Elsevier Inc. https://creativecommons.org/licenses/by/4.0/ Open Access under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/) license |
spellingShingle | Original Research Knapp, Susanne Warshow, Usama Ho, K.M. Alexander Hegazy, Doha Little, Ann–Margaret Fowell, Andrew Alexander, Graeme Thursz, Mark Cramp, Matthew Khakoo, Salim I. A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection |
title | A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection |
title_full | A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection |
title_fullStr | A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection |
title_full_unstemmed | A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection |
title_short | A Polymorphism in IL28B Distinguishes Exposed, Uninfected Individuals From Spontaneous Resolvers of HCV Infection |
title_sort | polymorphism in il28b distinguishes exposed, uninfected individuals from spontaneous resolvers of hcv infection |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194089/ https://www.ncbi.nlm.nih.gov/pubmed/21600205 http://dx.doi.org/10.1053/j.gastro.2011.04.005 |
work_keys_str_mv | AT knappsusanne apolymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT warshowusama apolymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT hokmalexander apolymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT hegazydoha apolymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT littleannmargaret apolymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT fowellandrew apolymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT alexandergraeme apolymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT thurszmark apolymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT crampmatthew apolymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT khakoosalimi apolymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT knappsusanne polymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT warshowusama polymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT hokmalexander polymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT hegazydoha polymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT littleannmargaret polymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT fowellandrew polymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT alexandergraeme polymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT thurszmark polymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT crampmatthew polymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection AT khakoosalimi polymorphisminil28bdistinguishesexposeduninfectedindividualsfromspontaneousresolversofhcvinfection |